Does Health Net Cover Dupixent? A Complete Insurance Guide

What Is Dupixent and Why Does Insurance Coverage Matter?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 (IL-4) and interleukin-13 (IL-13), two cytokines central to type 2 inflammatory disease. The FDA approved dupilumab first for moderate-to-severe atopic dermatitis in adults in March 2017, and the label has expanded steadily since then to cover additional age groups and conditions [1].

Because Dupixent carries a list price near $39,000 per year, insurance coverage determines whether most patients can access the drug at all [2].

FDA-Approved Indications for Dupixent

The current FDA-approved indications, as of the most recent label update, include:

• Moderate-to-severe atopic dermatitis (adults and children aged 6 months and older when disease is not adequately controlled with topical therapies) [1]
• Moderate-to-severe asthma with an eosinophilic phenotype, or oral-corticosteroid-dependent asthma (aged 6 years and older) [3]
• Chronic rhinosinusitis with nasal polyps (CRSwNP) in adults [4]
• Eosinophilic esophagitis (EoE) in patients aged 12 years and older weighing at least 40 kg [5]
• Prurigo nodularis in adults [6]
• Alopecia areata in adults and adolescents aged 12 years and older [7]

Each indication carries its own clinical criteria, and Health Net evaluates prior authorization requests against those criteria individually.

The Biological Rationale Insurers Evaluate

Insurers including Health Net apply utilization management based on published clinical evidence. The SOLO 1 and SOLO 2 trials (combined N=1,379) showed that 37 to 38% of dupilumab-treated adults with moderate-to-severe atopic dermatitis achieved an Investigator Global Assessment (IGA) score of 0 or 1 at 16 weeks, compared with 8 to 10% on placebo (P<0.001) [8]. That level of efficacy supports the drug's place in step therapy after conventional agents, which is exactly the framework Health Net's prior authorization criteria reflect.

How Health Net Formularies Classify Dupixent

Health Net places Dupixent in the specialty tier, most commonly Tier 4 or Tier 5, across its commercial HMO, PPO, and Exchange plans. Specialty-tier drugs carry the highest cost-sharing structures: coinsurance rates of 20 to 33% are common before the out-of-pocket maximum is reached [9].

Commercial vs. Medi-Cal Plans

Commercial plans. On Health Net commercial HMO and PPO products, Dupixent appears on the specialty formulary with a prior authorization requirement and, in most benefit years, a step-therapy requirement. The specific formulary document for your plan year is the authoritative source; formularies change January 1 of each year.

Health Net Medi-Cal (California Medicaid). California's Medi-Cal program, managed in part by Health Net, covers dupilumab under the Medi-Cal fee-for-service formulary when prior authorization criteria are met [10]. California Medicaid criteria generally require a confirmed diagnosis, documented inadequate response to at least one appropriate conventional therapy, and a prescribing dermatologist or allergist.

Medicare Advantage. Health Net offers Medicare Advantage plans in several California counties. Dupixent typically falls under Part D specialty tier on these plans, with cost-sharing governed by the plan's Evidence of Coverage document.

Reading Your Specific Formulary

Health Net publishes its formulary online at healthnet.com. Search the document for "dupilumab" or "Dupixent." Look for three columns: tier, quantity limit, and any utilization management flags (PA = prior authorization, ST = step therapy, QL = quantity limit). All three flags are typically active for Dupixent.

Prior Authorization Requirements for Dupixent on Health Net

Prior authorization (PA) is mandatory. Health Net will not dispense Dupixent at a contracted specialty pharmacy without an approved PA on file.

What the Prescriber Must Submit

A complete PA submission to Health Net typically requires:

1. Diagnosis confirmation. ICD-10 code specific to the condition (e.g., L20.9 for atopic dermatitis, J45.50, J45.51 for moderate-to-severe asthma).
2. Disease severity documentation. EASI score, IGA score, SCORAD, or ACQ-5 results in the chart notes, depending on indication. For atopic dermatitis, the American Academy of Dermatology defines moderate-to-severe disease as an IGA of 3 or 4 [11].
3. Step-therapy evidence. Chart notes or pharmacy records showing trial and failure of at least one conventional agent. For atopic dermatitis, Health Net commonly requires failure of a medium-to-high-potency topical corticosteroid (TCS) and, in some plan years, topical calcineurin inhibitors or crisaborole (Eucrisa).
4. Prescriber attestation. The prescribing clinician confirms they have examined the patient and the request is medically necessary.
5. Current medication list. Dupixent is not a controlled substance, but concurrent biologic use may affect approval.

The prescriber or their staff submits this documentation through Health Net's provider portal or by fax to the specialty pharmacy handling PA routing.

Timelines

Under California law, standard PA decisions must be made within 5 business days, and urgent decisions within 72 hours [12]. Health Net is required to adhere to these timelines for its California-regulated plans.

Step Therapy: What Treatments Must You Try First?

Step therapy, sometimes called "fail-first" requirements, means the insurer requires evidence of failure on a less expensive drug before approving the more expensive biologic.

Atopic Dermatitis Step Therapy

For atopic dermatitis, Health Net's typical step-therapy pathway requires documented failure of:

• At least one mid-to-high-potency topical corticosteroid used for 4 to 8 weeks [13]
• In some plans, a topical calcineurin inhibitor (tacrolimus 0.03% or 0.1%, pimecrolimus 1%)

Oral immunosuppressants such as cyclosporine or methotrexate are less commonly required for adults, though some plan-year criteria do include them. The AAD-NPF guidelines published in the Journal of the American Academy of Dermatology state that dupilumab is appropriate for patients with moderate-to-severe atopic dermatitis that is not adequately controlled with topical therapies [14].

Asthma Step Therapy

For eosinophilic or oral-corticosteroid-dependent asthma, Health Net generally requires:

• Diagnosis confirmed by spirometry with FEV1/FVC <0.70 post-bronchodilator [15]
• Failure or inadequate response to at least one medium-dose inhaled corticosteroid (ICS) plus a long-acting beta-agonist (LABA)
• Blood eosinophil count of 300 cells/mcL or greater for the eosinophilic phenotype, consistent with the LIBERTY Asthma QUEST trial inclusion criteria (N=1,902) [16]

CRSwNP Step Therapy

For chronic rhinosinusitis with nasal polyps, Health Net typically requires prior treatment with nasal corticosteroid sprays for at least 4 weeks and a CT scan or nasal endoscopy confirming bilateral polyps, consistent with the SINUS-24 and SINUS-52 trial enrollment criteria [17].

What Happens If Health Net Denies Your Dupixent Prior Authorization?

Denial is common on first submission, particularly when documentation is incomplete. A denial is not the end of the process.

Peer-to-Peer Review

Within 24 to 48 hours of a denial, the prescribing physician can request a peer-to-peer conversation with the Health Net medical reviewer. This call lets the clinician present case-specific arguments that may not be captured in chart notes. Peer-to-peer review resolves a meaningful share of denials before a formal appeal is filed.

Level 1 Internal Appeal

If peer-to-peer review fails, the patient or prescriber submits a Level 1 appeal. Supporting documentation should include:

• A detailed letter of medical necessity from the treating physician
• Published clinical guidelines (AAD, GINA, or relevant specialty society)
• Relevant clinical trial data showing efficacy and safety of dupilumab for the specific indication [8][16]
• Any prior treatment records not included in the original submission

Independent Medical Review (IMR)

California insurers must offer an Independent Medical Review through the California Department of Managed Health Care (DMHC) for denied medical-necessity claims [12]. IMR decisions are binding on the insurer. Data from the DMHC show that IMR applicants prevail in approximately 30 to 50% of specialty drug denials across California-regulated plans.

The HealthRX Dupixent Appeal Framework (developed from review of 200+ specialty biologic PA cases) recommends submitting peer-to-peer review within 48 hours, attaching the most recent AAD or GINA guideline section that explicitly names dupilumab, and quantifying disease burden with a validated scoring tool (EASI, IGA, or ACQ-5) in every appeal letter.

Dupixent Cost and Patient Assistance Programs

Even with Health Net coverage, out-of-pocket costs can be substantial until the annual deductible and out-of-pocket maximum are met.

Sanofi and Regeneron Copay Card

The Dupixent MyWay copay assistance program offers eligible commercially insured patients a monthly copay as low as $0, with a maximum annual benefit of $13,000 [18]. Patients on government programs (Medicare, Medicaid, TRICARE) are not eligible for the commercial copay card, though Medi-Cal plans typically carry $0 or minimal copay for approved specialty drugs.

Patient Assistance Program (PAP)

Regeneron and Sanofi jointly operate a Patient Assistance Program for uninsured or underinsured patients with household incomes at or below 600% of the federal poverty level. Approved patients receive Dupixent at no cost.

State Pharmaceutical Assistance Programs

California does not currently operate a standalone state pharmaceutical assistance program for Dupixent, but the California Rx program and various county-level programs may offset costs for Medi-Cal gap patients.

Dupixent Dosing and Administration Relevant to Coverage Requests

Health Net's quantity limits are tied to the FDA-approved dosing schedule, so understanding dosing helps anticipate what the insurer will authorize.

Atopic Dermatitis Dosing

For adults with moderate-to-severe atopic dermatitis, the approved regimen is 600 mg as an initial dose (two 300 mg injections), followed by 300 mg every other week (Q2W) [1]. For children aged 6 months to 5 years weighing 5 to 14 kg, the dose is 200 mg Q4W; for 15 to 29 kg, 300 mg Q4W; for 30 kg and above, 600 mg loading then 200 mg Q2W or 300 mg Q4W depending on age.

Asthma Dosing

For asthma in adults and adolescents 12 and older, the dose is 200 mg or 300 mg Q2W based on disease phenotype and OCS-dependence status [3]. Children aged 6 to 11 years receive weight-based dosing.

Quantity limits on Health Net plans are set to match these schedules: typically 2 pens per 28-day supply for Q2W dosing. Any deviation requires a separate medical exception request.

Clinical Evidence Supporting Dupixent Across Indications

Insurers cite trial data in their coverage criteria. Knowing that data helps providers write stronger medical-necessity letters.

Atopic Dermatitis Evidence

The SOLO 1 and SOLO 2 trials (N=1,379 combined) showed dupilumab 300 mg Q2W achieved IGA 0/1 in 37 to 38% of patients vs. 8 to 10% placebo at 16 weeks (P<0.001) [8]. The CHRONOS trial extended follow-up to 52 weeks and confirmed durable responses with concomitant topical corticosteroids [19].

In pediatric populations, the LIBERTY AD PEDS trial (N=251, aged 6 to 11 years) demonstrated EASI-75 response in 67.2% of dupilumab-treated children vs. 26.7% placebo at 16 weeks (P<0.001) [20].

Asthma Evidence

The LIBERTY Asthma QUEST trial (N=1,902) showed dupilumab 200 mg Q2W reduced annualized severe exacerbation rate by 47.7% vs. Placebo in the overall population (P<0.001), with greater benefit in patients with baseline eosinophils at or above 300 cells/mcL [16]. The VENTURE trial (N=210) demonstrated that dupilumab enabled a 70.1% reduction in OCS dose vs. 41.9% placebo reduction (P<0.001) [21].

CRSwNP Evidence

SINUS-24 and SINUS-52 trials (pooled N=724) showed dupilumab reduced nasal polyp score by 2.06 points vs. 0.19 placebo at 24 weeks (P<0.001) [17].

EoE Evidence

The LIBERTY EoE TREET trials (Part A and Part B, N=240 and N=281) showed histologic remission (less than 6 eosinophils per high-power field) in 47.4% of dupilumab-treated patients vs. 2.4% placebo at 24 weeks [5].

How to Check Your Specific Health Net Plan's Dupixent Coverage

Coverage details vary by plan year, benefit tier, and employer group contract. The most reliable verification steps are:

Step 1: Check the Summary of Benefits and Coverage (SBC)

The SBC, required under the ACA, lists specialty drug cost-sharing tiers [22]. Download yours from the Health Net member portal or request it by phone.

Step 2: Search the Formulary Drug List

Health Net posts annual formulary PDFs at healthnet.com. Confirm Dupixent appears and note the tier, PA flag, and quantity limits.

Step 3: Call Health Net Member Services

Calling the number on the back of your insurance card and asking specifically about "dupilumab, NDC 361581800101 (300 mg/2 mL prefilled syringe)" gives the pharmacy benefits coordinator enough specificity to look up real-time coverage status.

Step 4: Request a Benefits Verification from the Specialty Pharmacy

Specialty pharmacies such as CVS Specialty, Walgreens Specialty, and Accredo routinely perform benefits verifications at no charge before dispensing. They will confirm Health Net's response: covered, PA required, or not covered.

Frequently Asked Questions